Engineering Organ-on-a-Chip Systems for Vascular Diseases

A Shakeri, Y Wang, Y Zhao, S Landau… - … , and vascular biology, 2023 - Am Heart Assoc
Vascular diseases, such as atherosclerosis and thrombosis, are major causes of morbidity
and mortality worldwide. Traditional in vitro models for studying vascular diseases have …

Advances in cardiac tissue engineering and heart‐on‐a‐chip

J Kieda, A Shakeri, S Landau, EY Wang… - … Research Part A, 2024 - Wiley Online Library
Recent advances in both cardiac tissue engineering and hearts‐on‐a‐chip are grounded in
new biomaterial development as well as the employment of innovative fabrication …

[HTML][HTML] Real-time electro-mechanical profiling of dynamically beating human cardiac organoids by coupling resistive skins with microelectrode arrays

J Yin, JG Lees, S Gong, JT Nguyen, RJ Phang… - Biosensors and …, 2025 - Elsevier
Cardiac organoids differentiated from induced pluripotent stem cells are emerging as a
promising platform for pre-clinical drug screening, assessing cardiotoxicity, and disease …

Microvascular endothelial dysfunction in skin is associated with higher risk of heart failure with preserved ejection fraction in women with type 2 diabetes: the Hoorn …

ED Canto, L van Deursen, AG Hoek… - Cardiovascular …, 2023 - Springer
Background Microvascular dysfunction plays a crucial role in complications of type 2
diabetes and might contribute to heart failure with preserved ejection fraction (HFpEF), a …

Clinical trials in-a-dish for cardiovascular medicine

X Wu, K Swanson, Z Yildirim, W Liu… - European Heart …, 2024 - academic.oup.com
Cardiovascular diseases persist as a global health challenge that requires methodological
innovation for effective drug development. Conventional pipelines relying on animal models …

Harnessing human genetics and stem cells for precision cardiovascular medicine

A Caudal, MP Snyder, JC Wu - Cell Genomics, 2024 - cell.com
Human induced pluripotent stem cell (iPSC) platforms are valuable for biomedical and
pharmaceutical research by providing tissue-specific human cells that retain patients' …

Generation of human vascularized and chambered cardiac organoids for cardiac disease modelling and drug evaluation

J Yang, W Lei, Y **ao, S Tan, J Yang, Y Lin… - Cell …, 2024 - Wiley Online Library
Human induced pluripotent stem cell (hiPSC)‐derived cardiac organoids (COs) have shown
great potential in modelling human heart development and cardiovascular diseases, a …

Cell-cell interactions in the heart: advanced cardiac models and omics technologies

S Tan, J Yang, S Hu, W Lei - Stem Cell Research & Therapy, 2024 - Springer
A healthy heart comprises various cell types, including cardiomyocytes, endothelial cells,
fibroblasts, immune cells, and among others, which work together to maintain optimal …

Advances in the Generation of Constructed Cardiac Tissue Derived from Induced Pluripotent Stem Cells for Disease Modeling and Therapeutic Discovery

TJ Roland, K Song - Cells, 2024 - mdpi.com
The human heart lacks significant regenerative capacity; thus, the solution to heart failure
(HF) remains organ donation, requiring surgery and immunosuppression. The demand for …

[HTML][HTML] Model construction and clinical therapeutic potential of engineered cardiac organoids for cardiovascular diseases

Y Wang, Y Hou, T Hao… - Biomaterials …, 2024 - pmc.ncbi.nlm.nih.gov
Cardiovascular diseases cause significant morbidity and mortality worldwide. Engineered
cardiac organoids are being developed and used to replicate cardiac tissues supporting …